Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
OCOcular Therapeutix, Inc. logo

Ocular Therapeutix, Inc. (OCUL)

NASDAQ Global Market · Currency in USD
$6.50 ▼ -0.11 (-1.66%)
At close: Oct 23, 4:00 PM ET. Market closed.
$6.59 ▲ +0.09 (+1.38%)
Pre-market: Oct 26, 8:58 AM ET

Summary

Previous Close
$6.61
Open
$6.68
Day's Range
$6.35 – $6.68
52 Week Range
$6.00 – $16.44
Volume
1,855,969
Avg. Volume
2,984,442
Market Cap
$1.43B
Beta (5Y Monthly)
0.99
PE Ratio (TTM)
--
EPS (TTM)
-$1.34
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$23.00

Profile: Ocular Therapeutix, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
325
CEO
Pravin U. Dugel
Website
ocutx.com

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate -$0.36 · Revenue est. $14.27M
DateEst.Actual
Aug 3, 2026-$0.40-$0.35Beat
May 5, 2026-$0.32-$0.41Miss
Feb 5, 2026-$0.33-$0.29Beat
Nov 4, 2025-$0.39-$0.37Beat
Aug 5, 2025-$0.35-$0.39Miss
May 5, 2025-$0.29-$0.37Miss

Analyst view

Consensus price target
$23.00 ▲ +253.8%
Range $14.00 – $30.00
Rating: Buy
Buy 89% · Hold 11% · Sell 0%

Get free alerts on OCUL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.